logo
B02

Deciphering the role of BIRC3 in lymphomagenesis and resistance to therapy

Inactivating mutations in BIRC3 frequently occur in CLL and are associated with poor prognosis and resistance to therapy. BIRC3 encodes for the cellular inhibitor of apoptosis protein 2 (cIAP2) which is an E3 ligase that attaches ubiquitin chains to immune receptor signaling complexes, thereby regulating NF-κB signaling. NF-κB activation is known to provide pro-survival signals to leukemic cells and it induces the release of cytokines that can modulate tumor microenvironment. Therefore, the aim of the present proposal is to understand the role of cIAP2 aberrations in lymphomagenesis, resistance to therapy and tumor microenvironment.

PRINCIPAL INVESTIGATOR

Dr. rer. nat. Nieves Peltzer

Department of Translational Genomics

CMMC - Center for Molecular Medicine Cologne

University of Cologne

Robert-Koch-Straße 21

50931 Cologne

 

University of Cologne

Weyertal 115b

50931 Cologne

Prof. Dr. med. Christian Pallasch

Laboratory Tumor microenvironment and therapy resistance

Department I of Internal Medicine

University Hospital of Cologne

Kerpener Straße 62 

50937 Cologne